Miragen Therapeutics, Inc. (NASDAQ:MGEN) – Research analysts at B. Riley lifted their Q1 2018 earnings per share (EPS) estimates for Miragen Therapeutics in a note issued to investors on Thursday. B. Riley analyst M. Kumar now expects that the medical research company will post earnings per share of ($0.28) for the quarter, up from their prior forecast of ($0.36). B. Riley currently has a “Buy” rating and a $15.50 target price on the stock. B. Riley also issued estimates for Miragen Therapeutics’ Q2 2018 earnings at ($0.28) EPS, Q3 2018 earnings at ($0.28) EPS, Q4 2018 earnings at ($0.28) EPS, FY2018 earnings at ($1.11) EPS and FY2019 earnings at ($1.04) EPS.
Miragen Therapeutics (NASDAQ:MGEN) last released its earnings results on Wednesday, March 14th. The medical research company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. The company had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.22 million. Miragen Therapeutics had a negative return on equity of 63.57% and a negative net margin of 662.30%.
Several other analysts have also weighed in on MGEN. Wedbush reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Miragen Therapeutics in a research note on Friday, December 1st. Zacks Investment Research lowered Miragen Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th. Cann started coverage on Miragen Therapeutics in a research note on Friday, January 12th. They issued an “outperform” rating and a $13.00 price objective on the stock. Oppenheimer started coverage on Miragen Therapeutics in a research note on Friday, January 12th. They issued an “outperform” rating and a $13.00 price objective on the stock. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Miragen Therapeutics in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $16.82.
Shares of Miragen Therapeutics stock opened at $7.55 on Monday. The firm has a market capitalization of $224.78, a PE ratio of -5.03 and a beta of 1.64. The company has a debt-to-equity ratio of 0.26, a current ratio of 13.33 and a quick ratio of 13.33. Miragen Therapeutics has a 12 month low of $5.01 and a 12 month high of $15.91.
In other Miragen Therapeutics news, Director Thomas E. Hughes sold 12,000 shares of the stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $8.00, for a total value of $96,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce Booth bought 545,454 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was purchased at an average price of $5.50 per share, with a total value of $2,999,997.00. The disclosure for this purchase can be found here. 44.40% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. bought a new position in Miragen Therapeutics in the third quarter valued at about $147,000. Wells Fargo & Company MN raised its position in Miragen Therapeutics by 203.8% in the fourth quarter. Wells Fargo & Company MN now owns 17,804 shares of the medical research company’s stock valued at $185,000 after purchasing an additional 11,943 shares during the last quarter. SG Americas Securities LLC bought a new position in Miragen Therapeutics in the third quarter valued at about $250,000. Aveo Capital Partners LLC bought a new position in Miragen Therapeutics in the fourth quarter valued at about $279,000. Finally, Bank of New York Mellon Corp raised its position in Miragen Therapeutics by 67.1% in the fourth quarter. Bank of New York Mellon Corp now owns 45,775 shares of the medical research company’s stock valued at $478,000 after purchasing an additional 18,374 shares during the last quarter. Hedge funds and other institutional investors own 19.83% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Q1 2018 EPS Estimates for Miragen Therapeutics, Inc. Boosted by Analyst (MGEN)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/03/20/q1-2018-eps-estimates-for-miragen-therapeutics-inc-boosted-by-analyst-mgen.html.
About Miragen Therapeutics
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.